

Sudipto K. Chakrabortty¹, Robert R. Kitchen¹, Christine M. Coticchia¹, Erez Eitan¹, Michael D. Valentino¹, Vasisht R. Tadigotla¹, Elena Castellanos-Rizaldos¹, Lisa Bedford², Hidefumi Uchiyama³, Sunita Badola², Nicholas Colafemina¹, Mario Morken¹, Miguel Williams², Sylvie Vincent², Seth Yu¹ and Johan Skog¹ (1) Exosome Diagnostics, Inc. Waltham, MA (2) Takeda Pharmaceutical Co. Integrated Technology Research Laboratories, Fujisawa, Japan

- **Breast cancer is the most prevalent cancer in women**: ~250,000 diagnoses per year in the US
- Early detection is critical but current liquid biopsy approaches such as CTCs and cfDNA struggle to detect rare markers of disease
- Exosomes reflect active cellular processes thus enabling early cancer detection








- Exosome-based liquid biopsy is **minimally invasive** and **highly sensitive**, especially using **techniques to enhance signal-to-noise**:
- Able to enrich specific exosomal subpopulations originating from a tumor or any tissue of interest
- Able to **deplete non-relevant, non-cancerous exosomes** originating from abundant cell-types such as blood cells

Exosomal liquid biopsy reveals mRNA and lincRNA biomarkers in early stage



Sene set	fold enrichment	pValue (X ² , Bonf)	Gene set	fold enrichment	
Smirnov et al Circulating Endotheliocytes in Cancer Up	11.3	1.66E-11	Turashvili et al Breast Lobular Carcinoma vs Lobular Normal	17.61	
Schuetz et al. – Breast Cancer Ductal Invasive Up	5.7	1.79E-05	KEGG - ECM Receptor Interactions	16.33	
SMID - Breast Cancer Luminal A Up	10.9	7.05E-05	Hallmark - Estrogen response early	10.39	
GO – Regulation Of Immune System Process	3.04	4.31E-04	PID - Integrin1 Pathway	17.66	e
Reactome - Extracellular Matrix Organization	10.46	1.08E-04	Anastassiou et al. – Multi-cancer Invasiveness Signature	17.42	4
Durand et al Stroma Up	4.65	9.43E-03	Hallmark - Epithelial to Mesenchymal Transition	10.09	1
Mishra et al. – Carcinoma Associated Fibroblast Up	18.1	2.78E-03	Charafe et al. – Breast Cancer Luminal vs Mesenchymal	6.35	1

Contact: bd@exosomedx.com AACR Annual Meeting | April 14-18, 2018 | Chicago © 2018 Exosome Diagnostics, Inc.

